UK 
Our products
Epidyolex®
Cannabidiol (CBD)
Website
Product information
Patient information
Adverse event reporting
Side effects should be reported. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Adverse event reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue
Sativex®
Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
Website
Product information
Patient information
Adverse event reporting
Side effects should be reported. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk
Adverse event reporting forms and information can be found at www.hpra.ie/homepage/about-us/report-an-issue
Sativex distributors
We have developed and manufactured Sativex. All requests for product information and adverse events reporting should be directed through the distributor in that country/region.
Sativex is marketed in the UK by GW Pharmaceuticals If you are a medical professional and would like further information on Sativex® please contact us using the details below.
T +44 (0) 1223 238 170
E medinfo@gwpharm.com
Additional information:
Sativex Summary of Product Characteristics
Almirall S.A. is GW’s partner in Europe and therefore any enquiries relating to Sativex from medical professionals in Europe should be directed to Almirall using their website.
Sativex is approved and commercialized in the following countries in mainland Europe: Germany, Italy, Spain, Belgium, Luxembourg, Norway, Denmark, Sweden, Iceland, Portugal, Poland, Austria and Switzerland, while it is approved in France, Rep of Ireland, Finland, Czech Rep, Slovakia and The Netherlands but not yet available.
In all of these countries other than Switzerland the marketing authorization for Sativex is held by GW Pharma. The marketing authorization for Sativex in Switzerland is held by Almirall S.A.’s Swiss affiliate.
If you are a medical professional in Europe and would like further information on Sativex please contact Almirall using the following link:
Medical professionals wishing to obtain more information on Sativex in countries where it is awaiting approval should contact: medinfo@gwpharm.com